Biocept Comments on Reimbursement Provisions in CMS' Final PAMA Rule
"We commend CMS for its final PAMA rule that supports innovation in the diagnostics space and the timely market introduction of novel diagnostics products," said
"While we have yet to examine all implications of the PAMA rule, we now have greater transparency with regards to future
About
ADVI is a healthcare consulting firm specializing in policy, strategy, and commercial development for lifescience and healthcare services companies and organizations. ADVI has offices in
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the diagnosis
and treatment of cancer,
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-comments-on-reimbursement-provisions-in-cms-final-pama-rule-300291784.html
SOURCE
News Provided by Acquire Media